Be0060

Kras2^LSL/+ mice were on a C57BL/6-129/Sv mixed genetic background (14 (link)); all controls were littermates. A low dose of Cre-adenovirus (5 × 10⁵ PFU, University of Iowa, Iowa City, Iowa, USA) were administered intranasally to 6–7-week-old male and female mice. For xenograft experiments, NOD-SCID-γ mice (NSG) (NOD.Cg-Prkdc^scidIl2rg^tm1Wjl/SzJ, from Charles River Laboratories) were transplanted s.c. with 5 × 10⁵BACH1^–/–, BACH1^OE, or BACH1^–/–BACH1^OE A549 cells. When tumors were detected (i.e., reached 1–3 mm in size), the mice were injected i.p. with DC101 (40 mg/kg, BE0060, Bio X Cell) 3 times per week; control mice were injected with PBS. Tumor volume was measured 3 or 5 times per week with an electronic caliper and calculated as width² × length × 1/2, and tumors were weighed at the endpoint.

6–8 weeks old, male C57BL/6 mice were purchased from Shanghai Jihui Experimental Animal Breeding Co., Ltd. (Shanghai, China). Animals were housed and maintained under optimal conditions of light, temperature, and humidity with free access to food and water. For subcutaneous tumor model, a total of 1 × 10⁵ LA795 cells were resuspended in 200 µL PBS and inoculated subcutaneously into the right flank of mice. Tumor dimensions were measured by caliper every other day, and tumor volume (mm³) was estimated using the formula: tumor volume = (length) × (width)² × π/6. Different doses of anti-VEGFR2 antibody (DC101, BioXCell, BE0060) and IgG1 (BioXCell, BE0088) treatment were initiated 11 days after tumor cells inoculation and administered by intraperitoneal injection every 3 days. Anti-PD1 antibody (Anti-CD279, BioXCell, BE0146) and IgG2a (BioXCell, BE0089) treatment were initiated 12 days after tumor cells inoculation and was administered at 200 µg/mouse by intraperitoneal injection every 3 days. At indicated days later, the tumor-bearing mice were anesthetized and tissues were harvested for further analysis and measurement. Survival analysis was continued as independent experiments for indicated days.